Neuroprotective mechanisms of Bach1-Derepression in Alzheimer’s Disease
Neuroprotective mechanisms of Bach1-Derepression in Alzheimer’s Disease
批准号:
10434394
负责人:
MICHAEL K LEE
金额:
$225.36万
依托单位国家:
美国
项目类别:
财政年份:
2022
资助国家:
美国
项目状态:
未结题
起止时间:
2022-08-01 至 2025-07-31
关键词:
APP-PS1Alzheimer&aposs DiseaseAlzheimer&aposs disease brainAlzheimer&aposs disease modelAlzheimer&aposs disease pathologyAlzheimer&aposs disease therapeuticAlzheimer&aposs disease therapyAnimal ModelAntioxidantsAstrocytesBACH1 geneBehaviorBehavioralBindingBiochemicalCognitiveComplexCysteineDevelopmentDiseaseDisease ProgressionEtiologyEvaluationEventFunctional disorderGene ExpressionGene MutationGenesGeneticGoalsImpaired cognitionInterventionKnockout MiceKnowledgeMediatingMemoryMetallothioneinMicrogliaMusNerve DegenerationNeurodegenerative DisordersNeuronsNeuroprotective AgentsOnset of illnessOutcomeOxidative StressPPAR gammaPathogenesisPathway interactionsPatientsPharmaceutical PreparationsPharmacologyProteinsResponse ElementsRoleSignal PathwaySulfhydryl CompoundsTamoxifenTestingTherapeuticTherapeutic AgentsTherapeutic EffectTherapeutic InterventionTranscriptional RegulationUp-Regulationbasecell typeconditional knockoutderepressiondisease phenotypegene therapyheme oxygenase-1human modelimprovedin vivoinhibitorinnovationmitochondrial dysfunctionmouse Cre recombinasemouse modelneuroinflammationneuropathologyneuroprotectionnew therapeutic targetnovelnovel therapeutic interventionnuclear factor-erythroid 2pharmacophoreresponseside effecttranscription factor
中文摘要
项目摘要
阿尔茨海默病(AD)是一种不可逆转的进行性神经退行性疾病,它会缓慢地破坏
记忆中没有已知的治疗方法。虽然阿尔茨海默病的原因尚不清楚,但大量证据表明
氧化应激、线粒体功能障碍、神经炎症和蛋白质病都与AD有关
发病机制。核因子-红系2相关因子2(NRF2)是一种关键的转录因子,它能协调
多方面的反应调节AD涉及的多条致病途径。……的表达能力下降
在AD的人和动物模型中观察到Nrf2及其相关通路的改变。
因此,Nrf2通路的激活代表了AD的一种有前途的治疗方法。
不幸的是,经典的Nrf2激活剂是亲电性的,因为它们不仅与Kelch-like上的半胱氨酸反应-
ECH相关蛋白1(Keap1)激活Nrf2,但非特异性地与多种
导致副作用的细胞蛋白质。开发有效的基于NRF2的治疗药物的关键障碍
AD是目前对能够安全激活这一通路的机制缺乏了解。Btb(宽-
Complex(Tramtrack and bric-a-brac)和CnC(Cap‘n’Clear Protein)同源物1(Bach1)是一个转录因子
这抑制了Nrf2基因的表达。我们建议进行一项严格的评估来验证Bach1抑制
为AD发病机制的研究提供新的治疗策略,寻找新的干预靶点(S)。我们的中央
假说是,抑制Bach1对AD的行为和神经病理结果具有保护作用,这是由于
NRF2依赖和非NRF2依赖的机制。使用最先进的鼠标模型和新的非
亲电性Bach1抑制剂,我们建议a)描述Bach1抑制在Bach1抑制的发病和
阿尔茨海默病在体内的病理进展,b)确定Bach1在神经元、星形胶质细胞和
小胶质细胞调节AD的发育,c)区分Bach1和Nrf2依赖的通路
神经保护和d)确定治疗干预的新目标。建议的研究是基于
一个强有力的前提,并将使用创新的药理学和遗传学对该假说进行严格测试
干预措施。这些结果将提供关键的证据,证明抑制Bach1是一种新的治疗方法
将新型非亲电Bach1抑制剂作为潜在的AD治疗药物进行靶向和验证。
英文摘要
Project Summary
Alzheimer’s disease (AD) is an irreversible and progressive neurodegenerative disorder that slowly destroys
memory with no known cure. While the cause of AD is unknown, a large body of evidence suggests that
oxidative stress, mitochondrial dysfunction, neuroinflammation, and proteinopathy are all implicated in AD
pathogenesis. Nuclear-factor-erythroid 2-related factor 2 (Nrf2) is a key transcription factor that orchestrates a
multifaceted response to modulate multiple etiological pathways involved in AD. A decline in the expression of
Nrf2 and alteration of the Nrf2-related pathways are observed in humans and animal models of AD.
Consequently, activation of the Nrf2 pathway represents a promising therapeutic approach in AD.
Unfortunately, canonical Nrf2 activators are electrophiles as they not only react with cysteines on Kelch-like-
ECH-associated protein 1 (Keap1) to activate Nrf2 but non-specifically react with thiol groups on a variety of
cellular proteins resulting in side effects. A critical barrier to developing effective Nrf2-based therapeutics for
AD is the current lack of understanding of mechanisms that can safely activate this pathway. BTB (broad-
complex, tramtrack and bric-a-brac) and CNC (cap’n’collar protein) homology 1 (Bach1) is a transcription factor
that represses Nrf2 gene expression. We propose to conduct a rigorous evaluation to validate Bach1 inhibition
as a novel therapeutic strategy for AD pathogenesis and to identify new target(s) for intervention. Our central
hypothesis is that Bach1 inhibition protects against behavioral and neuropathological outcomes in AD due to
Nrf2-dependent and Nrf2-independent mechanisms. Using state of the art mouse models and novel non-
electrophilic Bach1 inhibitors, we propose to a) delineate the role of Bach1 inhibition in the onset and
progression of AD pathology in vivo, b) establish to what extent loss of Bach1 in neurons, astrocytes, and
microglia modulate AD development, c) differentiate between Bach1- and Nrf2-dependent pathways in
neuroprotection and d) identity novel targets for therapeutic interventions. The proposed studies are based on
a strong premise and will provide a rigorous test of the hypothesis using innovative pharmacologic and genetic
interventions. The outcomes will provide the critical evidence to justify Bach1 inhibition as a novel therapeutic
target and validate novel non-electrophilic Bach1 inhibitors as potential therapeutic agents for AD.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Regulation of human tau expression and tauopathy by alpha-synuclein
-
批准号:10464632
-
项目类别:
-
资助金额:$76.48万
-
财政年份:2022
-
负责人:MICHAEL K LEE
-
依托单位:
Regulation of human tau expression and tauopathy by alpha-synuclein
-
批准号:10622614
-
项目类别:
-
资助金额:$76.48万
-
财政年份:2022
-
负责人:MICHAEL K LEE
-
依托单位:
Alpha-Synuclein Induced Network Hyperexcitability in Lewy Body Dementias
-
批准号:10470990
-
项目类别:
-
资助金额:$84.03万
-
财政年份:2021
-
负责人:MICHAEL K LEE
-
依托单位:
Pathological role of c-Abl in alpha-synucleinoapathy
-
批准号:9896854
-
项目类别:
-
资助金额:$44.69万
-
财政年份:2016
-
负责人:MICHAEL K LEE
-
依托单位:
Pathological role of c-Abl in alpha-synucleinoapathy
-
批准号:9120184
-
项目类别:
-
资助金额:$44.11万
-
财政年份:2016
-
负责人:MICHAEL K LEE
-
依托单位:
Pathological role of c-Abl in alpha-synucleinoapathy
-
批准号:9452133
-
项目类别:
-
资助金额:$44.61万
-
财政年份:2016
-
负责人:MICHAEL K LEE
-
依托单位:
Unfolded Protein Response in Alpha-synucleinopathies
-
批准号:9203644
-
项目类别:
-
资助金额:$33.33万
-
财政年份:2014
-
负责人:MICHAEL K LEE
-
依托单位:
Unfolded Protein Response in Alpha-synucleinopathies
-
批准号:8639800
-
项目类别:
-
资助金额:$33.84万
-
财政年份:2014
-
负责人:MICHAEL K LEE
-
依托单位:
Unfolded Protein Response in Alpha-synucleinopathies
-
批准号:8990061
-
项目类别:
-
资助金额:$33.33万
-
财政年份:2014
-
负责人:MICHAEL K LEE
-
依托单位:
Unfolded Protein Response in Alpha-synucleinopathies
-
批准号:8789184
-
项目类别:
-
资助金额:$33.84万
-
财政年份:2014
-
负责人:MICHAEL K LEE
-
依托单位:
Neurodegenerative interactions in conditional LRRK2 Tg models
-
批准号:8457055
-
项目类别:
-
资助金额:$29.99万
-
财政年份:2011
-
负责人:MICHAEL K LEE
-
依托单位:
Neurodegenerative interactions in conditional LRRK2 Tg models
-
批准号:8664454
-
项目类别:
-
资助金额:$30.76万
-
财政年份:2011
-
负责人:MICHAEL K LEE
-
依托单位:
Neurodegenerative interactions in conditional LRRK2 Tg models
-
批准号:8296541
-
项目类别:
-
资助金额:$31.07万
-
财政年份:2011
-
负责人:MICHAEL K LEE
-
依托单位:
Neurodegenerative interactions in conditional LRRK2 Tg models
-
批准号:8204283
-
项目类别:
-
资助金额:$32.19万
-
财政年份:2011
-
负责人:MICHAEL K LEE
-
依托单位:
Abeta and Monoaminergic Neurodegeneration in Transgenic Mouse Models of AD
-
批准号:8423002
-
项目类别:
-
资助金额:$27.84万
-
财政年份:2009
-
负责人:MICHAEL K LEE
-
依托单位:
Abeta and Monoaminergic Neurodegeneration in Transgenic Mouse Models of AD
-
批准号:7759523
-
项目类别:
-
资助金额:$30.65万
-
财政年份:2009
-
负责人:MICHAEL K LEE
-
依托单位:
Abeta and Monoaminergic Neurodegeneration in Transgenic Mouse Models of AD
-
批准号:7598858
-
项目类别:
-
资助金额:$33.62万
-
财政年份:2009
-
负责人:MICHAEL K LEE
-
依托单位:
Pathological interactions of a-syn, mitochondria, and pesticides in PD models
-
批准号:7676967
-
项目类别:
-
资助金额:$50.94万
-
财政年份:2009
-
负责人:MICHAEL K LEE
-
依托单位:
Abeta and Monoaminergic Neurodegeneration in Transgenic Mouse Models of AD
-
批准号:8065485
-
项目类别:
-
资助金额:$29.46万
-
财政年份:2009
-
负责人:MICHAEL K LEE
-
依托单位:
Abeta and Monoaminergic Neurodegeneration in Transgenic Mouse Models of AD
-
批准号:8215817
-
项目类别:
-
资助金额:$29.46万
-
财政年份:2009
-
负责人:MICHAEL K LEE
-
依托单位: